Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Mufemilast by Tianjin Hemay Pharmaceutical for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
Mufemilast is under clinical development by Tianjin Hemay Pharmaceutical and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According...
Data Insights
Mufemilast by Tianjin Hemay Pharmaceutical for Ankylosing Spondylitis (Bekhterev's Disease): Likelihood of Approval
Mufemilast is under clinical development by Tianjin Hemay Pharmaceutical and currently in Phase II for Ankylosing Spondylitis (Bekhterev's Disease). According...